(1-ethyl-[3]piperidyl)-dimethyl-amine | 98952-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-ethyl-[3]piperidyl)-dimethyl-amine
• 英文别名: (1-Aethyl-[3]piperidyl)-dimethyl-amin；(3R)-1-ethyl-N,N-dimethylpiperidin-3-amine；1-ethyl-N,N-dimethylpiperidin-3-amine
• CAS: 98952-16-0
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: FUIUKWXBPSVXQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-氯-1-乙基哌啶 、 二甲胺 生成 (1-ethyl-[3]piperidyl)-dimethyl-amine
  参考文献：
  名称：

  DE812911

  摘要：

  公开号：

文献信息

• 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases
  申请人：Wagner Holger

  公开号：US20110269737A1

  公开（公告）日：2011-11-03

  The present invention provides compounds according to general formula (I) which are proposed for the treatment of respiratory complaints, particularly asthma and COPD.

  本发明提供了根据通用公式(I)的化合物，这些化合物被建议用于治疗呼吸系统疾病，特别是哮喘和慢性阻塞性肺病(COPD)。
• Aza-Substituted Spiro Derivatives
  申请人：Jitsuoka Makoto

  公开号：US20090258871A1

  公开（公告）日：2009-10-15

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）的化合物或其药学上可接受的盐：[其中X、Y、Z和W各自独立地表示甲基基团或氮原子，前提是当X、Y、Z和W全部为甲基基团时；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示甲基基团或氮原子；R表示由以下式子（II-1）表示的基团（其中R6、R7和R8各自独立地表示较低的烷基基团或类似物）。
• 1,7-DIAZACARBAZOLES AND METHODS OF USE
  申请人：Dyke Hazel Joan

  公开号：US20110183938A1

  公开（公告）日：2011-07-28

  The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  该发明涉及1,7-二氮杂咔唑化合物的公式（I）、（I-a）和（I-b），它们可用作激酶抑制剂，更具体地用作检查点激酶1（CHK1）抑制剂，因此可用作癌症治疗剂。该发明还涉及包含这些化合物的组合物，更具体地是药物组合物，以及使用它们治疗各种癌症和高增殖性疾病的方法，以及使用这些化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• AZA-SUBSTITUTED SPIRO DERIVATIVES
  申请人：Jitsuoka Makoto

  公开号：US20120149703A1

  公开（公告）日：2012-06-14

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）或其药学上可接受的盐的化合物： 其中X、Y、Z和W各自独立地表示一个甲基基团或氮原子，前提是X、Y、Z和W全部都是甲基基团的情况除外；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示一个甲基基团或氮原子；R表示以下式子（II-1）所表示的基团（其中R6、R7和R8各自独立地表示低级烷基或类似物）。
• Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof
  申请人：INVENTISBIO SHANGHAI LTD.

  公开号：US10179784B2

  公开（公告）日：2019-01-15

  The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).

  本发明公开了一类嘧啶或吡啶化合物、其药学上可接受的盐、立体异构体、原药和溶液剂、其制备方法和药物组合物及其药物用途。参见下文式 I。这些化合物可以抑制表皮生长因子受体蛋白酶的变体，因此可以有效抑制多种肿瘤细胞的生长。这些化合物可用于制备抗肿瘤药物，用于治疗、联合治疗或预防各种不同的癌症。这些化合物可以克服现有的第一代表皮生长因子受体抑制剂（如吉非替尼、厄洛替尼等）引起的耐药性。特别是，这些化合物可用于制备治疗或预防由表皮生长因子受体变体（如 L858R 激活突变体、Exon19 缺失激活突变体和 T790M 耐药突变体）介导的疾病、紊乱、失调或病症的药物。